

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) An *E.coli* host cell ~~expressing a recombinant antibody characterized in that the *E.coli* host cell has been genetically modified in order to change at least one physical property of one or more *E.coli* proteins which in the wild type co-purify with said recombinant antibody~~ comprising at least one genetic alteration that results in modification of at least one physical property of at least one endogenous protein that, when unmodified, co-purifies with a recombinant antibody expressed by the host cell.
2. (currently amended) The host cell of claim 1 where the physical ~~characteristic~~ property of the ~~*E.coli*~~ endogenous protein that is ~~altered~~ modified is the isoelectric point, hydrophobicity or size.
3. (currently amended) The host cell of claim 2 where the physical ~~characteristic~~ property of the ~~*E.coli*~~ endogenous protein that is ~~altered~~ modified is the isoelectric point.
4. (currently amended) The host cell of ~~claims 1 to 3~~ claim 1 where the ~~altered host modified endogenous~~ protein is Phosphate binding protein (PhoS/PstS), Dipeptide binding protein (DppA), Maltose binding protein (MBP) or thioredoxin 1.
5. (currently amended) The host cell of ~~claims 1 to 3~~ claim 1 where the ~~altered host modified endogenous~~ protein is Phosphate binding protein (PhoS/PstS).
6. (currently amended) The host cell of claim 4 where the isoelectric point of the ~~host endogenous~~ protein is ~~altered~~ modified by the addition of a poly-aspartic acid tag to the C-terminus.
7. (currently amended) The host cell of claim 5 where the isoelectric point of the Phosphate binding protein (PhoS/PstS) ~~has been~~ is reduced by substituting one or more lysines at residues 110, 265, 266 or 318 with glutamine or aspartic acid.

8. (currently amended) The host cell of claim 7 where the isoelectric point of the Phosphate binding protein (PhoS/PstS) ~~has been~~ is reduced further by the addition of a poly-aspartic acid tag to the C-terminus.

9. (currently amended) The host cell of claim 5 where the isoelectric point of the Phosphate binding protein (PhoS/PstS) ~~has been~~ is reduced by substituting the lysines at residues 265 and 266 with glutamine and by the addition of a poly-aspartic acid tag to the C-terminus.

10. (currently amended) The host cell of claim 5 where the isoelectric point of the Phosphate binding protein (PhoS/PstS) ~~has been~~ is reduced by substituting the lysines at residues 110, 265 and 266 with glutamine and by the addition of a poly-aspartic acid tag to the C-terminus.

11. (currently amended) The host cell of ~~claims 1-10~~ claim 1 ~~where~~ wherein the recombinant antibody is a Fab or a Fab' fragment.

12. (currently amended) A method of manufacturing a recombinant antibody ~~which comprises~~ comprising fermenting a host cell ~~according to claims 1-11 of claim 1.~~